Efficacy and safety of long-term tildrakizumab for moderate to severe chronic plaque psoriasis: 3-year results from reSURFACE 1

被引：0
作者：
Tyring, S. [1 ]
Spelman, L. [2 ,3 ]
Igarashi, A. [4 ]
Ohtsuki, M. [5 ]
Li, Q. [6 ]
Mendelsohn, A. [7 ]
Parno, J. [7 ]
Guenthner, S. [8 ]
机构：
[1] Univ Texas Houston, Dept Dermatol, UTHlth, Houston, TX USA
[2] Verac Clin Res, Brisbane, Qld, Australia
[3] Prob Med Res, Waterloo, ON, Canada
[4] NNT Med Ctr Tokyo, Tokyo, Japan
[5] Jichi Med Univ Hosp, Shimotsuke, Tochigi, Japan
[6] Merck & Co Inc, Kenilworth, NJ USA
[7] Sun Pharmaceut Ind Inc, Princeton, NJ USA
[8] Indiana Univ Sch Med, Indianapolis, IN 46202 USA
来源：
AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2019年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：61 / 61
页数：1
相关论文
共 50 条
[31]   Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks (vol 182, pg 605, 2020) [J].
Reich, K. ;
Warren, R. B. ;
Iversen, L. .
BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (01) :131-132
[32]   Adalimumab long-term safety/efficacy results for pediatric patients with chronic plaque psoriasis from a phase 3, randomized study [J].
Papp, Kim ;
Marcoux, Danielle ;
Landells, Ian ;
Weibel, Lisa ;
Ghislain, Pierre-Dominique ;
Unnebrink, Kristina ;
Williams, David .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) :AB209-AB209
[33]   Long-term clinical safety and efficacy of brodalumab in the treatment of Japanese patients with moderate-to-severe plaque psoriasis [J].
Umezawa, Y. ;
Nakagawa, H. ;
Niiro, H. ;
Ootaki, K. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 (11) :1957-1960
[34]   A network meta-analysis of long-term efficacy and safety of treatments for moderate-to-severe plaque psoriasis [J].
Armstrong, A. ;
Soliman, A. ;
Betts, K. ;
Wang, Y. ;
Gao, Y. ;
Stakias, V. ;
Puig, L. .
BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (01) :E33-E33
[35]   Long-Term Efficacy, Safety and Drug Survival of Ustekinumab in a Spanish Cohort of Patients with Moderate to Severe Plaque Psoriasis [J].
Puig, Lluis ;
Ruiz-Salas, Veronica .
DERMATOLOGY, 2015, 230 (01) :46-54
[36]   Long-term efficacy of tildrakizumab in patients with moderate-to-severe psoriasis who were partial responders or non-responders to etanercept: results from the reSURFACE 2 phase 3 trial through 148 weeks [J].
Iversen, L. ;
Reich, K. ;
Griffiths, C. ;
Peserico, A. ;
Kimball, A. ;
Pau-Charles, I. ;
Blauvelt, A. ;
Thaci, D. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 :56-56
[37]   Sustained long-term Efficacy of Ustekinumab over 3 Years in Patients with moderate to severe Plaque Psoriasis [J].
Ghislain, P-D ;
Poulin, Y. ;
Wasel, N. ;
Menter, A. ;
Sofen, H. ;
Yeilding, N. ;
Fakharzadeh, S. ;
Li, S. ;
Leonardi, C. .
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2011, 9 :195-195
[38]   Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study [J].
Valenzuela, F. ;
Korman, N. J. ;
Bissonnette, R. ;
Bakos, N. ;
Tsai, T. -F. ;
Harper, M. K. ;
Ports, W. C. ;
Tan, H. ;
Tallman, A. ;
Valdez, H. ;
Gardner, A. C. .
BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (04) :853-862
[39]   Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial [J].
Igarashi, Atsuyuki ;
Kato, Takeshi ;
Kato, Mai ;
Song, Michael ;
Nakagawa, Hidemi .
JOURNAL OF DERMATOLOGY, 2012, 39 (03) :242-252
[40]   Efficacy outcomes during extended and long-term use of efalizumab in patients with moderate to severe chronic plaque psoriasis [J].
Papp, K ;
Menter, A ;
Leonardi, C ;
Lynde, C ;
Ouellet, J ;
Toth, D ;
Rosoph, L ;
Carey, W .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2004, 123 (02)
12345